Estrogen Patch in Newly Postmenopausal Women May Reduce Alzheimer’s Risk

Summary: According to a new study, amyloid deposition is reduced in newly postmenopausal women who received a estrogen replacement therapy.

Source: Mayo Clinic.

Can estrogen preserve brain function and decrease the risk of Alzheimer’s disease when given early in menopause? Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer’s disease, a Mayo Clinic study published this month in the Journal of Alzheimer’s Disease found. Ultimately, these deposits harm neurons, leading to cognitive problems.

In the study, women with APOE e4 — one form of the most common gene associated with late-onset Alzheimer’s disease — had lower levels of amyloid deposits.

“This study showed, for the first time, that the brain amyloid deposition — a hallmark of Alzheimer’s disease — is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,” says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist. “Women with APOE e4, who have a greater genetic risk for Alzheimer’s disease, particularly benefited from this therapy.”

Menopause is defined as occurring 12 months after a woman’s last menstrual period and marks the end of menstrual cycles. In the U.S., the average age of menopause is 51. A rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer’s disease risk in women.

The Women’s Health Initiative study by the National Institutes of Health (NIH) reported that menopausal hormone therapy started in women 65 or older increased the risk of dementia. In contrast, the multicenter Kronos Early Estrogen Prevention Study tested the hypothesis that healthy and younger women would respond to menopausal hormone therapy more favorably.

The Mayo Clinic study used data from the Kronos study to determine the effects of menopausal hormone therapy shortly after menopause, during the critical window of rapid estrogen depletion — five to 36 months past menopause. Researchers investigated the brain amyloid deposition in 68 women ages 42 to 59 who participated in the Kronos trial during this critical window. The researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.

An alzheimer's brain slice.

Menopause is defined as occurring 12 months after a woman’s last menstrual period and marks the end of menstrual cycles. In the U.S., the average age of menopause is 51. A rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer’s disease risk in women. NeuroscienceNews.com image is for illustrative purposes only.

Of the 68 women, 21 received estrogen via a skin patch, 17 received estrogen orally and 30 received a placebo. Amyloid deposition was lower in women who received the patch, compared to the placebo, and the effect was most apparent in women with the APOE e4 genotype. The oral treatment was not associated with lower amyloid deposition.

The authors are seeking funding to perform amyloid PET imaging at eight more Kronos Early Estrogen Prevention study sites around the U.S.

“If our results are confirmed in the larger group of women, this finding has the potential to change the concepts for preventive interventions that drive the Alzheimer’s disease field today,” Dr. Kantarci says. “It also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years.”

About this Alzheimer’s disease research article

Study co-authors are Val Lowe, M.D.; Timothy Lesnick, M.S.; Nirubol Tosakulwong; Kent Bailey, Ph.D.; Julie Fields, Ph.D.; Lynne Shuster, M.D.; Samantha Zuk; Matthew Senjem M.S.; Michelle Mielke, Ph.D.; Clifford Jack Jr., M.D.; Walter Rocca, M.D.; and Virginia Miller, Ph.D., all of Mayo Clinic; and Carey Gleason, Ph.D., of University of Wisconsin School of Medicine and Public Health.

Funding: This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute and NIH. (NS66147, AG029624, AG44170)

Source: Susan Barber Lindquist – Mayo Clinic
Image Source: This NeuroscienceNews.com image is in the public domain.
Original Research: Full open access research for “Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition” by Kantarci, Kejal; Lowe, Val J.; Lesnick, Timothy G.; Tosakulwong, Nirubol; Bailey, Kent R.; Fields, Julie A.; Shuster, Lynne T.; Zuk, Samantha M.; Senjem, Matthew L.; Mielke, Michelle M.; Gleason, Carey; Jack, Clifford R.; and Rocca, Walter A. Miller, Virginia M.h in Journal of Alzheimer’s Disease. Published online May 7 2016 doi:10.3233/JAD-160258

Cite This NeuroscienceNews.com Article
Mayo Clinic. “Estrogen Patch in Newly Postmenopausal Women May Reduce Alzheimer’s Risk.” NeuroscienceNews. NeuroscienceNews, 12 July 2016.
<http://neurosciencenews.com/estrogen-alzheimers-menopause-4669/>.
Mayo Clinic. (2016, July 12). Estrogen Patch in Newly Postmenopausal Women May Reduce Alzheimer’s Risk. NeuroscienceNews. Retrieved July 12, 2016 from http://neurosciencenews.com/estrogen-alzheimers-menopause-4669/
Mayo Clinic. “Estrogen Patch in Newly Postmenopausal Women May Reduce Alzheimer’s Risk.” http://neurosciencenews.com/estrogen-alzheimers-menopause-4669/ (accessed July 12, 2016).

Abstract

Suicide among people with epilepsy: A population-based analysis of data from the U.S. National Violent Death Reporting System, 17 states, 2003–2011

Background: It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer’s disease (AD).

Objective: To investigate the effects of hormone therapy on amyloid-β deposition in recently postmenopausal women.

Methods: Participants within 5–36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45 mg/day oral conjugated equine estrogens (CEE); 2) 50μg/day transdermal 17β-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200 mg/day) was given to active treatment groups for 12 days each month. 11C Pittsburgh compound B (PiB) PET imaging was performed in 68 of the 118 participants at Mayo Clinic approximately seven years post randomization and three years after stopping randomized treatment. PiB Standard unit value ratio (SUVR) was calculated.

Results: Women (age = 52–65) randomized to transdermal 17β-estradiol (n = 21) had lower PiB SUVR compared to placebo (n = 30) after adjusting for age [odds ratio (95% CI) = 0.31(0.11–0.83)]. In the APOE ɛ4 carriers, transdermal 17β-estradiol treated women (n = 10) had lower PiB SUVR compared to either placebo (n = 5) [odds ratio (95% CI) = 0.04(0.004–0.44)], or the oral CEE treated group (n = 3) [odds ratio (95% CI) = 0.01(0.0006–0.23)] after adjusting for age. Hormone therapy was not associated with PiB SUVR in the APOE ɛ4 non-carriers.

Conclusion: In this pilot study, transdermal 17β-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-β deposition, particularly in APOE ɛ4 carriers. This finding may have important implications for the prevention of AD in postmenopausal women, and needs to be confirmed in a larger sample.

“Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition” by Kantarci, Kejal; Lowe, Val J.; Lesnick, Timothy G.; Tosakulwong, Nirubol; Bailey, Kent R.; Fields, Julie A.; Shuster, Lynne T.; Zuk, Samantha M.; Senjem, Matthew L.; Mielke, Michelle M.; Gleason, Carey; Jack, Clifford R.; and Rocca, Walter A. Miller, Virginia M.h in Journal of Alzheimer’s Disease. Published online May 7 2016 doi:10.3233/JAD-160258

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.
No more articles